News

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME.

Updates include expected timelines for trials for the treatment of wet AMD, DME, GA, and inherited retinal diseases.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

This partnership will provide Greater Tampa Bay community with services for the treatment of uveitis and retina care.

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

If granted, this device would be assigned an official classification as a Class II device with special controls.

Data will be shared in early 2024 regarding this potential treatment of diabetic retinopathy via eye drop.

According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.

A specialist in the field of ophthalmology and gene therapy, Dr Girach’s appointment enhances SpliceBio’s leadership team as it accelerates lead program targeting Stargardt disease towards clinical development.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

According to the company, the designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular degeneration.

A look back at some of the biggest stories in ophthalmology in 2023.

From FDA approvals to innovations in lens tech, 2023 was a big year in eye care.

A review of Ophthalmology Times Europe's most important content from throughout the year.

Catch up on a few of our top stories and ones you may have missed in 2023

Scientists have developed a versatile imaging system that will help diagnose pathologies in the eye fundus.

The suspension is unrelated to product quality and will lift in February of 2024.

During a multidisciplinary meeting with FDA, based on preliminary results from an ongoing Phase 1/2 study, the company received alignment on key points of the Phase 3 study design.

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

According to the company, if approved, OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME.